Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
vaccine
|
| gptkbp:administeredBy |
intramuscular injection
|
| gptkbp:alsoKnownAs |
FINLAY-FR-2
|
| gptkbp:approvedBy |
July 2021
|
| gptkbp:boosters |
gptkb:Soberana_Plus
|
| gptkbp:clinicalTrialPhase |
Phase III
|
| gptkbp:containsAntigen |
SARS-CoV-2 spike protein RBD
|
| gptkbp:countryOfOrigin |
gptkb:Cuba
|
| gptkbp:developedBy |
gptkb:Finlay_Institute
|
| gptkbp:dosingSchedule |
two doses, 28 days apart
|
| gptkbp:efficacyAgainstSymptomaticCOVID19 |
approximately 62% after two doses
|
| gptkbp:efficacyWithBooster |
over 90% with Soberana Plus booster
|
| gptkbp:emergencyServices |
gptkb:Cuba
|
| gptkbp:foundIn |
gptkb:Iran
gptkb:Nicaragua gptkb:Venezuela |
| https://www.w3.org/2000/01/rdf-schema#label |
Soberana 02 vaccine
|
| gptkbp:storage |
2-8°C
|
| gptkbp:target |
gptkb:COVID-19
|
| gptkbp:type |
vaccine
|
| gptkbp:WHOStatus |
not yet approved by WHO
|
| gptkbp:bfsParent |
gptkb:BioCubaFarma
|
| gptkbp:bfsLayer |
7
|